Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q1 FY27 Earnings Presentation
32 slides from Syngene International's earnings presentation, Jul 29, 2026
Slide 1: Regulation 30 cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2026-27/Jul/18 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 29, 2026 To, To, The Manager, Th
Slide 2: Investor Presentation July 2026
Investor Presentation July 2026
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Q1 FY27 Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Putting Science to Work 3
Slide 5: Q1 FY27 Highlights
1 Q1 FY27 Highlights Syngene
Slide 6: Q1 FY27 performance
Q1 FY27 performance Operating Highlights Q1 FY27 Financial Highlights • Siddharth Mittal assumed charge as Managing Director & CEO on July 1, 2026 Revenue from Operations Rs 736 Cr ( -16% Y-o-Y) • Signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Instit
Slide 7: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 8: Partner in innovation: Who we are and what we do
Partner in innovation: #Putting Science to Work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more than Established track record in solutions across pharmaceuticals, b
Slide 9: Our journey so far
Our journey so far 2019 – 2026 Globalization and strategic collaboration Continued investments and growth • Expanded into formulations development • Laboratory capacity expansion in Bangalore • Contract with Endo Pharmaceuticals to develop novel anti cancer and Hyderabad biological therapeutic molec
Slide 10: Key facts and figures
Key facts and figures ~400 16 out of top 20 400+ World class infrastructure active clients pharma companies are patents International presence with global clients held with clients campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standa
Slide 11: Syngene – one of the largest integrated CRDMO players in India
Syngene – one of the largest integrated CRDMO players in India One-stop platform for integrated drug discovery, development and manufacturing across modalities Expanding capacity Building capabilities for future Building partnerships (in Million sq. ft.) (#) (#) ~3 8,373 ~400 0.9 3,526 250+ March’16
Slide 12: 3-pronged growth strategy across diversified platform
3-pronged growth strategy across diversified platform Research Services (CRO) Discovery Services Dedicated R&D Centers T&CR Large Molecule CDMO Small Molecule CDMO Flexible Platform with capability Ring-fenced infrastructure for Comprehensive research services Process development Drug substance and
Slide 13: Our Strategy
Our Strategy Research Services Development and Development and Manufacturing Services – Manufacturing Services – Provide an integrated end-to-end Large Molecules Small Molecules therapeutic discovery services Encompassing drug discovery, pre- Utilize existing Chemistry, Manufacturing, Implement a co
Slide 14: Syngene strengths
3 Syngene strengths Syngene
Slide 15: Syngene strengths
Syngene strengths A global scale CRDMO player Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track
Slide 16: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers Inspiring technical excellence and providing opportunities to grow • Thrive360 operating philosophy embedding wellbeing into how work is designed and 8,373 total headcount delivered - supporting physical, mental & emotional, social, financial
Slide 17: Extended our state-of-the-art infrastructure & new capabilities with global presence
Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs USA based Biologics facility HQ campus at Bangalore, India Fully functional Bayview, Baltimore, where most of Syngene’s capabilities are R&D Centre at USA housed today Genome Val
Slide 18: We currently operate a range of successful collaboration models
We currently operate a range of successful collaboration models Dedicated R&D Labs • Customers receive ring-fenced infrastructure customized to Full time equivalent (FTE) • A dedicated team of scientific personnel from predefined Fee For service (FFS) • Services are provided within a defined scope R
Slide 19: Our experience spans multiple industry segments and partners us with global leaders
Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid-Sized Emerging Chemicals/ BioPharma BioPharma (EBP) Animal Health AgroChem CPG Polymers Note : This is a representative selection of the customers Syngene works with. We work with ~ 400
Slide 20: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded through a Focused execution through strong Project structured Lean Six Sigma framework Management Certification pathway from White Belt to Master Black Belt Structured program management for executing client 90+ Green
Slide 21: Syngene digital initiatives aimed at driving innovation and operational excellence
Syngene digital initiatives aimed at driving innovation and operational At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve Certification as per ISO 13485:2016, ISO/IEC scientific and enterprise functions. 27001
Slide 22: Committed to safety and sustainability
Committed to safety and sustainability Safety is our first priority • Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures • Risk assessments are an integral part of our operation • Kavach, our flagship safety program, has delivered improvement in safety metrics and driv
Slide 23: Accreditations
Accreditations • USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities. • GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory • GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Ass
Slide 24: Industry recognition for scientific capability and business excellence
We have consistently received industry recognition for our scientific capability and business excellence • EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma
Slide 25: Enterprise-wide risk oversight with clear accountability
Syngene has established an enterprise-wide risk oversight with clear accountability from management to the Board Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance Operating Unit
Slide 26: Financials
4 Financials
Slide 27: Q1 FY27 financial highlights
Q1 FY27 financial highlights All figures in Rs. Cr unless otherwise specified Particulars Q1 FY27 Q1 FY26 YoY change Balance Sheet Highlights Revenue from operations 736 875 -16% Other income 25 18 43% As on 30th June 2026 All figures in Rs. Cr unless otherwise specified Reported revenue 761 892 -1
Slide 28: FY26 financial highlights
FY26 financial highlights All figures in Rs. Cr unless otherwise specified Particulars FY26 FY25 YoY change Balance Sheet Highlights Revenue from operations 3,739 3,642 3% Other income 71 71.8 -1% As on 31st March 2026 All figures in Rs. Cr unless otherwise specified Reported revenue 3,809 3,714 3%
Slide 29: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 30: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 31: Shareholding and Share Information
Shareholding and Share Information Syngene’s shareholding* Syngene’s Share Information* NSE Ticker SYNGENE 0.4% BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Cr) 17,741 47% 53% Public % free-float^ 47% ESOP Trust Free-float market cap (Rs. Cr) 8,411 Share Outstanding (Cr) 40 • As on 30
Slide 32: For more details
For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Nandini Agarwal Vijay Jeevanandham investor@syngeneintl.com E: Vijay.jeevanandham@syngeneintl.com
Syngene International — Q1 FY27 Earnings Presentation on 6ix